Yahoo! Finance Search - Finance Home - Yahoo! - Help

Saturday, May 30 2015 12:24pm ET - U.S. Markets Closed.
Industry Center - Drugs - Generic
Industry Center > Drugs - Generic > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drugs - Generic News
Latest News
Friday, May 29, 2015
·Business Highlights
AP - Fri 6:11 pm ET
·Top Drug Stock: Acquisitions Drive Mallinckrodt's Success
at Investor's Business Daily, Inc. - Fri 5:31 pm ET
·US appeals court: Alzheimer's drug swap is anti-competitive
AP - Fri 1:44 pm ET
Thursday, May 28, 2015
·Is Top-Rated Drug Stock Actavis Ready To Rally Again?
at Investor's Business Daily, Inc. - Thu 5:40 pm ET
·UPDATE 1-FDA asks dermal filler makers to indicate risk of serious injury
Reuters - Thu 4:56 pm ET
·Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) at the European Society of Human Genetics Annual Meeting 2015
GlobeNewswire - Thu 4:05 pm ET
·Amarin's Lawsuit Could Have Huge Benefits For Pharma Industry And Dire Consequences For Consumers
at Forbes.com - Thu 3:46 pm ET
·Valeant, Actavis Neck And Neck With Bowel Disorder Drugs
- Thu 2:41 pm ET
·With A $1.2 Billion Hammer, The FTC Closes Loophole To Prevent Generic Drugs
at Forbes.com - Thu 1:40 pm ET
·FDA asks dermal filler makers to indicate risk of serious injury
Reuters - Thu 1:14 pm ET
·Actavis, Valeant Up On Bowel-Disease Drug Approvals
at Investor's Business Daily, Inc. - Thu May 28
·Buy Actavis For Its High Growth, Low Valuation Says Citi
at Barrons.com - Thu May 28
·Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer
GlobeNewswire - Thu May 28
·Zoetis: A Bet On Activism
at Forbes.com - Thu May 28
·Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2015 Financial Results and Conference Call
GlobeNewswire - Thu May 28
·Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma
GlobeNewswire - Thu May 28
·Agile Therapeutics to Present at the William Blair 35th Annual Growth Stock Conference
GlobeNewswire - Thu May 28
·MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R)
Marketwire - Thu May 28
·Rigel to Present at Jefferies 2015 Global Healthcare Conference
PR Newswire - Thu May 28
·Galectin Therapeutics to Present at LD Micro Invitational Conference
GlobeNewswire - Thu May 28
More Latest News...
Sponsor Results
In-Person Training Course
Global Regulatory Strategy. Asia-Pacific and Emerging Markets
www.DIAHome.org/OnlineTraining
M/A/R/C Research
Custom Research
www.MARCresearch.com
This Just In
New Industry Insights Regarding Industry News.
Newsroom.ChainStoreGuide.com
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drugs - Generic Headlines
More Finance RSS Feeds


Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?